CRYZL1 (crystallin zeta like 1) is a component of the FERRY complex (Five-subunit Endosomal Rab5 and RNA/ribosome intermediary), a protein complex consisting of TBCK, PPP1R21, FERRY3, CRYZL1, and GATD1 1. The FERRY complex functions as a RAB5A effector that directly interacts with mRNAs and mediates their endosomal transport and localization, particularly recruiting mRNAs and ribosomes to early endosomes for local translation in cells with extended processes 2. CRYZL1 is ubiquitously expressed across multiple tissues including heart, brain, skeletal muscle, kidney, pancreas, liver, and lungs 3. CRYZL1's involvement in mRNA trafficking and localization suggests relevance to neurological function. While mutations in other FERRY complex members (TBCK, PPP1R21, FERRY3) cause neurogenetic disorders characterized by intellectual disability and neurodegeneration, no neurologic disorders have yet been associated with CRYZL1 mutations 1. However, plasma CRYZL1 levels demonstrate complex disease associations: Mendelian randomization studies identified CRYZL1 as a protective factor against vascular dementia (OR = 0.387) 4, while showing positive causal association with hepatocellular carcinoma risk 5. In lung adenocarcinoma, CRYZL1 expression is regulated by BRINP3 through CLOCK-mediated transcriptional mechanisms and contributes to tumor progression via AKT pathway activation 6. These findings suggest CRYZL1 may have context-dependent roles in neuronal homeostasis and cancer pathogenesis.